Study supports PSA screening for male BRCA2 carriers

Study supports PSA screening for male <i>BRCA2</i> carriers

(HealthDay)—Systematic prostate-specific antigen (PSA) screening is advised for men who are carriers of the BRCA2 mutation, which is associated with a higher incidence of prostate cancer, younger age at diagnosis, and clinically significant tumors, according to the interim results of a study published in the December issue of European Urology.

Elizabeth C. Page, from the Institute of Cancer Research in London, and colleagues evaluated the utility of targeted using PSA in men with pathogenic, germline BRCA1/2 mutations and controls (919 BRCA1 carriers, 709 BRCA1 noncarriers, 902 BRCA2 carriers, and 497 BRCA2 noncarriers).

The researchers found that after three years of screening, 527 men had PSA >3.0 ng/mL, 357 biopsies were performed, and 112 prostate cancer cases were diagnosed (31 BRCA1 carriers, 19 BRCA1 noncarriers, 47 BRCA2 carriers, and 15 BRCA2 noncarriers). In BRCA2 carriers, the cancer incidence rate was higher than in noncarriers (19.4 versus 12.0 per 1,000 person years). BRCA2 carriers were diagnosed at a younger age (61 versus 64 years) and were more likely to have clinically significant disease compared with BRCA2 noncarriers (77 versus 40 percent). There were no differences in age or tumor characteristics between BRCA1 carriers and BRCA1 noncarriers. Compared with PSA alone (area under the curve, 0.65), the 4 kallikrein marker model discriminated better (area under the curve, 0.73) for clinically significant at biopsy.

"We recommend that male BRCA2 carriers are offered systematic PSA screening," the authors write.

Several authors disclosed financial ties to the diagnostics industry.

Explore further

Early first cancer in BRCA1/2 ups risk in opposite breast

More information: Abstract/Full Text
Journal information: European Urology

Copyright © 2019 HealthDay. All rights reserved.

Citation: Study supports PSA screening for male BRCA2 carriers (2019, November 27) retrieved 13 August 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors